

Cg-Xxx-Gly	(5)	
Cg-Xxx-Hyn	(6)	
Cg-Xxx-Pro	(7)	
Cg-Xxx-His	(8)	
Cg-Xxx-Met	(9)	
Cg-Xxx-Ala	(10)	
Cg-Xxx-Hyn	(11)	
Cg-Xxx-Ala-Gly	(12)	
Cg-(Xxx) _n -Xxx-Gly	(13)	SEQ ID NO.:1
Cg-(Xxx) _n -Xxx-Ala-Gly	(14)	SEQ. ID NO.: 2

wherein

Cg represents a capping group selected from pyridinyloxycarbonyl, pyridinylacetyl, pyridinylmethylsulfonyl and pyridylmethylaminocarbonyl;

Xxx represents a moiety derived from an amino carboxylic acid; and

n is an integer from 1 to 6. --

At page 28 please replace the first paragraph with the following re-written paragraph:

--Example 7

Synthesis of Pyridin-3-ylmethoxycarbonyl-Pro-Ala-Gly-Pro-OH (SEQ. ID NO.: 3) --

At page 30 please replace the last paragraph with the following re-written paragraph:

--Example 21

Synthetic procedures of doxorubicin conjugates

21 Pyridin-3-ylmethoxycarbonyl-Pro-Ala-Gly-Pro-Doxorubicin (SEQ. ID NO.: 4)
Pyridin-3-ylmethoxycarbonyl-Pro-Ala-Gly-Pro-OH (SEQ. ID. NO.: 3) (180.7 mg, 0.38 mmol) and N-hydroxysuccinimide (44 mg, 0.37 mmol) were weighed out and placed in a 2 neck-round bottom flask under dinitrogen. Anhydrous *N,N*-dimethylformamide (20 ml)

was added and the flask was cooled to 0 °C in an ice bath. Dicyclohexylcarbodiimide (78 mg, 0.38 mmol) was added as a 1 ml solution in N,N-dimethylformamide. The solution was stirred at 0 °C for 40 minutes. --

At page 41 please replace the first paragraph with the following re-written paragraph:

At page 41 please replace the third paragraph with the following re-written paragraph:

--Example 56

Synthesis of Pyridin-3-ylmethoxycarbonyl-Pro-Ala-Gly-Pro-MNA (SEQ. ID. NO. 5) --

At page 42 please replace the first paragraph with the following re-written paragraph:

--

MNA-Conjugate	% Turnover	Cleavage [μM]	SEQ. ID NO.
4-Amino-Phenylacetyl-Gly-Pro-MNA	0.6	3	
3,5-Difluorphenylacetyl-Gly-Pro-MNA	2.26	2.26	
2-Fluorphenylacetyl-Gly-Pro-MNA	0.26	1.28	
3-Fluorphenylacetyl-Gly-Pro-MNA	0.35	1.77	
4-Fluorphenylacetyl-Gly-Pro-MNA	0.42	2.08	
3-Pyridylacetyl-Gly-Pro-MNA	1.82	9.12	
3-Pyridylmethyloxycarbonyl-Gly-Pro-MNA	0.72	3.58	
4-Pyridylmethyloxycarbonyl-Gly-Pro-MNA	1.18	5.92	
3-Pyridylmethyloxycarbonyl-Pro-Ala-Gly-Pro-MNA	1.77	8.86	5
4-Pyridylmethyloxycarbonyl-Pro-Ala-Gly-Pro-MNA	1.28	6.38	6
4-Aminomethylbenzoyl-Pro-Ala-Gly-Pro-MNA	0.24	1.21	7
4-Aminomethylphenylacetyl-Pro-Ala-Gly-Pro-MNA	0.26	1.28	8
4-(2-Aminothiazol-5-yl)-acetyl-Pro-Ala-Gly-Pro-	0.39	1.94	9